Want to see HK:2268 full AI Analyst Report?
2268 Stock Chart & Stats
HK$55.55
-HK$0.65(-1.20%)
At close: 4:00 PM EDT
HK$55.55
-HK$0.65(-1.20%)
Day’s Range― - ―
52-Week RangeHK$43.50 - HK$85.50
Previous CloseN/A
Volume2.89M
Average Volume (3M)6.66M
Market Cap
HK$65.60B
Enterprise ValueHK$74.47K
Total Cash (Recent Filing)HK$7.47B
Total Debt (Recent Filing)HK$879.52M
Price to Earnings (P/E)37.1
Beta0.94
Next Earnings
Aug 24, 2026EPS Estimate
0.8Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.20
Shares Outstanding1,266,364,100
10 Day Avg. Volume10,688,598
30 Day Avg. Volume6,656,062
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)6.72
Price to Sales (P/S)12.13
P/FCF Ratio113.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$80.77Price Target Upside45.40% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)1.49
Revenue Forecast (FY)HK$8.04B
Bulls Say, Bears Say
Bulls Say
Revenue & ProfitabilityConsistent double-digit revenue growth to 5.79B and sustained high net (~24.9%) and EBIT (~27.3%) margins reflect structural demand for complex CDMO services. This durable top-line and margin profile supports reinvestment in capacity and R&D, enabling long-term customer wins and scalable profitability if execution remains consistent.
Conservative Balance SheetA very low debt-to-equity ratio (~0.08) and substantial equity base provide financial flexibility to fund capital-intensive biologics manufacturing, absorb R&D and capex cycles, and pursue strategic investments without heavy reliance on external financing, improving multi‑period resilience and downside protection.
Specialized CDMO PositioningA focused, integrated offering around ADCs and bioconjugation creates high technical barriers to entry and sticky customer relationships. Specialized capabilities across development and commercialization support pricing power, repeat program wins and diversified service revenue over time, strengthening competitive moat in a niche, growing segment.
Bears Say
Volatile Cash ConversionFree cash flow volatility and weak cash conversion (2025 FCF ~34% of net income after a negative prior year) mean reported earnings do not consistently translate into discretionary cash. This undermines the firm's ability to self-fund expansion, raises financing risk for capex-heavy projects and reduces confidence in earnings quality over the medium term.
Margin Compression RiskObserved compression across gross, EBITDA and net margins versus the prior year suggests rising cost intensity as the business scales. If structural cost pressures or mix shifts persist, maintaining historically strong margins will require operational improvements or pricing power, otherwise long‑term profitability and return profiles may erode.
Declining Capital EfficiencyReturn on equity falling from ~16.1% to ~13.4% signals reduced capital efficiency: incremental earnings are yielding less shareholder return. This may reflect heavier reinvestment, margin mix shifts, or underutilized capacity and can persistently limit shareholder returns unless productivity or margin recovery occurs.
WuXi XDC Cayman, Inc. News
2268 FAQ
What was WuXi XDC Cayman, Inc.’s price range in the past 12 months?
WuXi XDC Cayman, Inc. lowest stock price was HK$43.50 and its highest was HK$85.50 in the past 12 months.
What is WuXi XDC Cayman, Inc.’s market cap?
WuXi XDC Cayman, Inc.’s market cap is HK$65.60B.
When is WuXi XDC Cayman, Inc.’s upcoming earnings report date?
WuXi XDC Cayman, Inc.’s upcoming earnings report date is Aug 24, 2026 which is in 16 days.
How were WuXi XDC Cayman, Inc.’s earnings last quarter?
WuXi XDC Cayman, Inc. released its earnings results on Mar 23, 2026. The company reported HK$0.706 earnings per share for the quarter, missing the consensus estimate of HK$0.718 by -HK$0.012.
Is WuXi XDC Cayman, Inc. overvalued?
According to Wall Street analysts WuXi XDC Cayman, Inc.’s price is currently Undervalued.
Does WuXi XDC Cayman, Inc. pay dividends?
WuXi XDC Cayman, Inc. does not currently pay dividends.
What is WuXi XDC Cayman, Inc.’s EPS estimate?
WuXi XDC Cayman, Inc.’s EPS estimate is 0.8.
How many shares outstanding does WuXi XDC Cayman, Inc. have?
WuXi XDC Cayman, Inc. has 1,266,364,100 shares outstanding.
What happened to WuXi XDC Cayman, Inc.’s price movement after its last earnings report?
WuXi XDC Cayman, Inc. reported an EPS of HK$0.706 in its last earnings report, missing expectations of HK$0.718. Following the earnings report the stock price went down -4.06%.
Which hedge fund is a major shareholder of WuXi XDC Cayman, Inc.?
Currently, no hedge funds are holding shares in HK:2268
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
WuXi XDC Cayman, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
HK$80.77 (45.40% Upside)
HK$80.77 (45.40% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
226.79%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
65.58%
Trailing 12-Months
Company Description
WuXi XDC Cayman, Inc.
WuXi XDC Cayman Inc. operates as an investment holding company and a global contract research, development, and manufacturing organization (CRDMO), with operations spanning China, North America, Europe, and other international regions. The company's expertise covers the entire lifecycle, from discovery and research to development and manufacturing, of biopharmaceutical products. Specifically, it focuses on antibody-drug conjugates (ADCs), various bioconjugates, monoclonal antibody intermediates, and the crucial payload-linkers integral to bioconjugate synthesis. Founded in 2013 and headquartered in Wuxi, China, WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc.
2268 Stock 12 Month Forecast
Average Price Target
HK$80.77
▲(45.40% Upside)
Technical Analysis
Wuxi Biologics (Cayman)
―
Hangzhou Tigermed Consulting Co., Ltd. Class H
―
Pharmaron Beijing Co., Ltd. Class H
―
WuXi AppTec Co., Ltd. Class H
―
Asymchem Laboratories (Tianjin) Co., Ltd. Class H
―